TransMedics Group

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade TransMedics Group 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About TMDX

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. 

CEO
Waleed H. Hassanein
CEOWaleed H. Hassanein
Employees
728
Employees728
Headquarters
Andover, Massachusetts
HeadquartersAndover, Massachusetts
Founded
1998
Founded1998
Employees
728
Employees728

TMDX Key Statistics

Market cap
4.39B
Market cap4.39B
Price-Earnings ratio
51.91
Price-Earnings ratio51.91
Dividend yield
Dividend yield
Average volume
635.36K
Average volume635.36K
High today
$127.50
High today$127.50
Low today
$127.50
Low today$127.50
Open price
$133.00
Open price$133.00
Volume
606.00
Volume606.00
52 Week high
$156.00
52 Week high$156.00
52 Week low
$62.07
52 Week low$62.07

Stock Snapshot

With a market cap of 4.39B, TransMedics Group(TMDX) trades at $127.50. The stock has a price-to-earnings ratio of 51.91.

During the trading session on 2026-02-13, TransMedics Group(TMDX) shares reached a daily high of $127.50 and a low of $127.50. At a current price of $127.50, the stock is 0.0% higher than the low and still 0.0% under the high.

Trading activity shows a volume of 606, compared to an average daily volume of 635.36K.

The stock's 52-week range extends from a low of $62.07 to a high of $156.00.

The stock's 52-week range extends from a low of $62.07 to a high of $156.00.

TMDX News

TipRanks 3d
TransMedics: Robust Early 2026 Demand and DCD Leadership Underpin Buy Rating and Revenue Growth Outlook

William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on TransMedics Group. The associated price target remains the same with $148.00....

Simply Wall St 5d
Should TransMedics’ Pivot to Full-Service Organ Logistics and Global OPO Programs Require Action From TMDX Investors?

TransMedics Group recently reported strong year-over-year revenue growth, expanded its dedicated organ transport aviation fleet, and moved further toward a recu...

Should TransMedics’ Pivot to Full-Service Organ Logistics and Global OPO Programs Require Action From TMDX Investors?

Analyst ratings

77%

of 13 ratings
Buy
76.9%
Hold
23.1%
Sell
0%

People also own

Based on the portfolios of people who own TMDX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.